HealthX Connect Osaka 2026

1 Jul 2026 | Osaka, Japan

InvestmentUpdated on 23 June 2026

Pre-Series A equity fundraise

Clinical Director at CanSense Ltd

About

CanSense has raised £1.5M (JPY32M) in seed investment and £2.4M (JPY514M) in non-dilutive funding to bring its colorectal cancer diagnostic blood test to market in the UK. With regulatory milestones achieved and international patents awarded CanSense seek investment to expand into other global territories and expand it's indications to other cancer types.

Stage

  • Series A | Scale business

Organisation

CanSense Ltd

Company (SME/startup) / 中小企業・スタートアップ

Swansea, United Kingdom

Similar opportunities